AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P05231

UPID:

IL6_HUMAN

Alternative names:

B-cell stimulatory factor 2; CTL differentiation factor; Hybridoma growth factor; Interferon beta-2

Alternative UPACC:

P05231; Q9UCU2; Q9UCU3; Q9UCU4

Background:

Interleukin-6 (IL-6), known by alternative names such as B-cell stimulatory factor 2 and Interferon beta-2, plays a pivotal role in immunity, tissue regeneration, and metabolism. It operates through binding to IL6R and IL6ST/gp130, initiating various signaling pathways crucial for biological functions including the acute phase response, differentiation of B and T cells, bone homeostasis, and metabolic control.

Therapeutic significance:

IL-6's involvement in diseases like Rheumatoid arthritis systemic juvenile highlights its dual role in both host defense and disease pathology. Its excessive synthesis is linked to severe complications, making it a target for therapeutic strategies aiming to modulate its activity for treating inflammatory disorders and potentially other IL-6 related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.